Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Esophageal and Gastroenterological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Esophagus. 2022 Oct;19(4):576-585. doi: 10.1007/s10388-022-00921-w. Epub 2022 May 7.
Cervical esophageal cancer (CEC) carries a poor prognosis; however, due to its low incidence, optimal treatment for CEC remains to be established. The purpose of this study was to clarify the current status of treatment of CEC in Japan and obtain evidence for establishing the appropriate treatment method.
We asked specialist training facilities accredited by the Japanese Broncho-Esophageal Society to register data on CEC cases that received curative treatment from January 2009 to December 2014, and conducted a retrospective review of the clinical data of 302 cases registered from 27 facilities.
In regard to the initial therapy, of the 302 patients, 33 had undergone endoscopic resection, 41 had undergone surgery, 67 had received induction chemotherapy (IC), and 143 had received chemoradiotherapy (CRT). There were no significant differences in the 5-year overall survival rates among the patient groups that had received surgery, IC or CRT as the initial treatment; advanced stage and recurrent nerve invasion were identified as independent poor prognostic factors. Among the patients who had received IC or CRT as laryngeal-preserving surgery was not indicated at the time of the initial diagnosis, the functional laryngeal preservation rate at the end of the observation period was 34.8%.
Even in patients with advanced CEC, there is the possibility of preserving the larynx by adopting IC or CRT. However, if the laryngeal function cannot be preserved, there is a risk of complications from aspiration pneumonia, so that the choice of treatment should be made carefully.
颈段食管癌(CEC)预后较差;然而,由于其发病率低,CEC 的最佳治疗方法仍有待确定。本研究旨在阐明日本 CEC 的治疗现状,为确立合适的治疗方法提供依据。
我们要求日本支气管食管学会认可的专科培训机构登记 2009 年 1 月至 2014 年 12 月期间接受根治性治疗的 CEC 病例数据,并对 27 家机构登记的 302 例病例的临床数据进行回顾性分析。
在初始治疗方面,302 例患者中,33 例行内镜下切除术,41 例行手术,67 例行诱导化疗(IC),143 例行放化疗(CRT)。手术、IC 或 CRT 作为初始治疗的患者 5 年总生存率无显著差异;晚期和喉返神经侵犯是独立的不良预后因素。在初始诊断时不适合行保留喉功能的 IC 或 CRT 的患者中,观察期末功能保留喉的比例为 34.8%。
即使是晚期 CEC 患者,采用 IC 或 CRT 也有可能保留喉部。然而,如果不能保留喉功能,有发生吸入性肺炎并发症的风险,因此应慎重选择治疗方法。